# Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)

> **NCT01840579** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 57 (actual)

## Conditions studied

- Solid Tumor
- Non-small Cell Lung Cancer
- Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab 2 mg/kg
- **BIOLOGICAL:** Pembrolizumab 10 mg/kg
- **BIOLOGICAL:** Pembrolizumab 200 mg
- **DRUG:** Cisplatin 75 mg/m^2
- **DRUG:** Pemetrexed 500 mg/m^2
- **DRUG:** Carboplatin AUC 5 mg/mL/min
- **DRUG:** Carboplatin AUC 6 mg/mL/min
- **DRUG:** Paclitaxel 200 mg/m^2
- **DRUG:** Nab-paclitaxel 100 mg/m^2
- **BIOLOGICAL:** Ipilimumab 1 mg/kg
- **DRUG:** Etoposide 100 mg/m^2
- **DRUG:** G-CSF (pegfilgrastim) 3.6 mg

## Key facts

- **NCT ID:** NCT01840579
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-26
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-02-28
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2021-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01840579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01840579, "Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01840579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*